Please assess the completion status of the following clinical trial:

Trial Title: Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of pancreas localized to the pancreas, small bowel, stomach and/or encasing the superior mesenteric artery, vein or portal vein. (a.k.a. Stage IV A).~* No prior chemotherapy for their pancreatic cancer or radiation to the area of the tumor.~* Measurable disease: Any mass reproducibly measurable in two perpendicular diameters by x-ray, physical examination, CT or MRI scans.~* Ineligible for other high priority national or institutional studies~* Whipple surgery not allowed. Prior surgery is allowed as long as it was not pancreatic resection (i.e. Whipple surgery) and the time from surgical recovery is greater than three weeks.~* Non pregnant females who are not breast feeding with a negative serum β-HCG test within 1 week of starting the study. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.~* Clinical Parameters~  * Life expectancy \> 2 months.~ * Age 18 to 70 years old~ * Performance status 0-2 (ECOG). (See Appendix IV)~ * Peripheral Neuropathy must be \< grade 1~ * Able to tolerate oral medications~ * Absolute Neutrophil Count \> 1,500 μl~ * White Blood Count \> 3,000/μl~ * Platelet count \> 100,000/μl~ * BUN \< 1.5 x normal~ * Creatinine \< 1.5 normal~ * Hemoglobin \> 8.0 g/dl~ * Serum Albumin \> 2.5 mg/dl~ * Total Bilirubin \< 5.0 mg/dl~ * SGOT, SGPT, Alkaline Phosphatase \< 4.0 x ULN~Exclusion Criteria:~* Hypersensitivity: Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80 must be excluded.~* Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.~* Prior malignancies in last 5 years other than: curatively treated carcinoma in-situ of the cervix, non-melanoma skin cancer, prostate or DCIS (ductal carcinoma in-situ) previously treated successfully (cancer free)~* No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection).~* Patients known to have HIV will be excluded.~* Patients cannot have received any prior investigational agent/therapy, nor will they be allowed any investigational agent/therapy while on protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GTX and Radiation Therapy with Gemzar (Type: EXPERIMENTAL): Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).